A MULTICENTER DOUBLE BLIND RANDOMIZED SINGLE DOSE ACTIVE-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SYNTHETIC SURFACTANT (CHF 5633) IN COMPARISON TO PORCINE SURFACTANT (PORACTANT ALFA CUROSURF?) IN THE TREATMENT OF PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME.
G
Gregory Sokol, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
100 years or below
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to compare a new surfactant (CHF 5633) investigational drug with a similar standard product on the market also manufactured by CHIESI, Poractant Alfa.
Detailed description of study
The purpose of this study is to compare a new surfactant (CHF 5633) investigational drug with a similar standard product on the market also manufactured by CHIESI, Poractant Alfa.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: neonatal respiratory distress syndrome
-
Age: 100 years or below
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1603300738
